US regulatory status: approved.
pharma · Colorectal Cancer · Esophageal Varices in NASH Cirrhosis · GALT
Galectin Therapeutics
GALECTIN THERAPEUTICS INC
Galectin Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US HQ
2000 Founded
36 Employees
Public company Type
GALT · NYSE Ticker
Company details
- Status
- Public
- HQ
- 4960 Peachtree Industrial Boulevard, Suite 240, Norcross, GA 30071, US
- Founded
- 2000
- Employees
- 36
- Programs
- 12
- Drugs
- 5
- Patents
- 20
Galectin Therapeutics pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Galectin Therapeutics drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
anti-melanoma mab fragments
Various (V09)Various (V09) compound in Galectin Therapeutics's portfolio. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to Galectin Therapeutics in public FDA and regional records.
-
Development asset linked to Galectin Therapeutics in public FDA and regional records.